cki 7 profile

N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide: casein kinase I inhibitor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide : A member of the class of isoquinolines that is isoquinoline-8-sulfonamide which is substituted by chlorine at position 5 and in which the sulfonamide nitrogen is substituted by a 2-aminoethyl group. It is an inhibitor of casein kinase I. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	129236
CHEMBL ID	489157
CHEBI ID	47322
SCHEMBL ID	3491587
MeSH ID	M0163873

Synonym
5-chloro-isoquinoline-8-sulfonic acid, (2-amino-ethyl)-amide
n-(2-aminoethyl)-5-chloro-isoquinoline-8-sulfonamide
cki-7
NCGC00165762-01
DB03693
2CSN ,
CKI ,
n-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide
cki 7
120615-25-0
FT-0661792
CHEMBL489157
chebi:47322 ,
bdbm92674
isoquinolinesulfonamide, cki-7
unii-3ie84w82o5
3ie84w82o5 ,
8-isoquinolinesulfonamide, n-(2-aminoethyl)-5-chloro-
n-(2-aminoethyl)-5-chloroisoquinoline-8-sulphonamide
SCHEMBL3491587
W-205095
DTXSID20152934
AKOS027446743
mfcd00269886
CS-0109499
HY-133028
cki-7 (free base)
Q27094604
n-(2-aminoethyl)-5-chloro-8-isoquinolinesulfonamide
cki-7;
MS-24070

Excerpt	Reference	Relevance
"The phosphorylation of insulin-like growth factor binding protein-I (IGFBP-1) alters its binding affinity for insulin-like growth factor I (IGF-I) and thus regulates the bioavailability of IGF-I for binding to the IGF-I receptor."	( Characterization of insulin-like growth factor binding protein-1 kinases from human hepatoma cells. Ankrapp, DP; Clemmons, DR; Jones, JI, 1996)	0.29

Role	Description
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor	An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of non-specific serine/threonine protein kinase (EC 2.7.11.1), a kinase enzyme involved in phosphorylation of hydroxy group of serine or threonine.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
sulfonamide	An amide of a sulfonic acid RS(=O)2NR'2.
isoquinolines	A class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
organochlorine compound	An organochlorine compound is a compound containing at least one carbon-chlorine bond.
primary amino compound	A compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, CASEIN KINASE-1	Schizosaccharomyces pombe (fission yeast)	Ki	39.0000	39.0000	39.0000	39.0000	AID977610
Calcium/calmodulin-dependent protein kinase II inhibitor 2	Bos taurus (cattle)	IC50 (µMol)	399.0833	3.6000	6.5500	9.5000	AID1799819
cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)	IC50 (µMol)	399.0833	3.6000	6.5500	9.5000	AID1799819
Protein kinase C alpha type	Homo sapiens (human)	IC50 (µMol)	399.0833	0.0001	0.9720	10.0000	AID1799819
Casein kinase I isoform alpha	Homo sapiens (human)	IC50 (µMol)	301.7500	0.0010	2.2499	10.0000	AID1539765; AID1799819; AID684955
Casein kinase I isoform delta	Homo sapiens (human)	IC50 (µMol)	9.5000	0.0040	1.1272	10.0000	AID1539765
Casein kinase I isoform epsilon	Homo sapiens (human)	IC50 (µMol)	9.5000	0.0040	1.1150	9.5000	AID1539765
Casein kinase II subunit alpha	Homo sapiens (human)	IC50 (µMol)	399.0833	0.0005	1.3332	10.0000	AID1799819
Casein kinase I isoform gamma-2	Homo sapiens (human)	IC50 (µMol)	9.5000	0.0040	3.2634	9.5000	AID1539765
Casein kinase I isoform delta	Oryctolagus cuniculus (rabbit)	IC50 (µMol)	10.0000	10.0000	10.0000	10.0000	AID448718
Casein kinase I isoform gamma-1	Homo sapiens (human)	IC50 (µMol)	9.5000	0.0040	4.7163	9.5000	AID1539765
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
mesoderm formation	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
regulation of protein phosphorylation	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
negative regulation of gene expression	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
positive regulation of insulin secretion	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
sarcomere organization	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
negative regulation of activated T cell proliferation	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
cardiac muscle cell proliferation	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
cellular response to glucagon stimulus	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
angiogenesis	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Protein kinase C alpha type	Homo sapiens (human)
desmosome assembly	Protein kinase C alpha type	Homo sapiens (human)
chromatin remodeling	Protein kinase C alpha type	Homo sapiens (human)
protein phosphorylation	Protein kinase C alpha type	Homo sapiens (human)
mitotic nuclear membrane disassembly	Protein kinase C alpha type	Homo sapiens (human)
cell adhesion	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of endothelial cell migration	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of cardiac muscle hypertrophy	Protein kinase C alpha type	Homo sapiens (human)
peptidyl-serine phosphorylation	Protein kinase C alpha type	Homo sapiens (human)
peptidyl-threonine phosphorylation	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of cell migration	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathway	Protein kinase C alpha type	Homo sapiens (human)
negative regulation of glial cell apoptotic process	Protein kinase C alpha type	Homo sapiens (human)
regulation of mRNA stability	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	Protein kinase C alpha type	Homo sapiens (human)
post-translational protein modification	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of macrophage differentiation	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of angiogenesis	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of bone resorption	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of cell adhesion	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of mitotic cell cycle	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Protein kinase C alpha type	Homo sapiens (human)
response to interleukin-1	Protein kinase C alpha type	Homo sapiens (human)
regulation of platelet aggregation	Protein kinase C alpha type	Homo sapiens (human)
apoptotic signaling pathway	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of angiotensin-activated signaling pathway	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of dense core granule biogenesis	Protein kinase C alpha type	Homo sapiens (human)
intracellular signal transduction	Protein kinase C alpha type	Homo sapiens (human)
positive regulation of insulin secretion	Protein kinase C alpha type	Homo sapiens (human)
protein phosphorylation	Casein kinase I isoform alpha	Homo sapiens (human)
Golgi organization	Casein kinase I isoform alpha	Homo sapiens (human)
cell surface receptor signaling pathway	Casein kinase I isoform alpha	Homo sapiens (human)
Wnt signaling pathway	Casein kinase I isoform alpha	Homo sapiens (human)
peptidyl-serine phosphorylation	Casein kinase I isoform alpha	Homo sapiens (human)
viral protein processing	Casein kinase I isoform alpha	Homo sapiens (human)
cellular response to nutrient	Casein kinase I isoform alpha	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Casein kinase I isoform alpha	Homo sapiens (human)
positive regulation of Rho protein signal transduction	Casein kinase I isoform alpha	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	Casein kinase I isoform alpha	Homo sapiens (human)
intermediate filament cytoskeleton organization	Casein kinase I isoform alpha	Homo sapiens (human)
cell division	Casein kinase I isoform alpha	Homo sapiens (human)
negative regulation of canonical Wnt signaling pathway	Casein kinase I isoform alpha	Homo sapiens (human)
negative regulation of NLRP3 inflammasome complex assembly	Casein kinase I isoform alpha	Homo sapiens (human)
positive regulation of TORC1 signaling	Casein kinase I isoform alpha	Homo sapiens (human)
signal transduction	Casein kinase I isoform alpha	Homo sapiens (human)
microtubule nucleation	Casein kinase I isoform delta	Homo sapiens (human)
Golgi organization	Casein kinase I isoform delta	Homo sapiens (human)
protein localization to Golgi apparatus	Casein kinase I isoform delta	Homo sapiens (human)
protein localization to cilium	Casein kinase I isoform delta	Homo sapiens (human)
protein localization to centrosome	Casein kinase I isoform delta	Homo sapiens (human)
non-motile cilium assembly	Casein kinase I isoform delta	Homo sapiens (human)
positive regulation of protein phosphorylation	Casein kinase I isoform delta	Homo sapiens (human)
protein phosphorylation	Casein kinase I isoform delta	Homo sapiens (human)
Wnt signaling pathway	Casein kinase I isoform delta	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Casein kinase I isoform delta	Homo sapiens (human)
circadian regulation of gene expression	Casein kinase I isoform delta	Homo sapiens (human)
regulation of circadian rhythm	Casein kinase I isoform delta	Homo sapiens (human)
COPII vesicle coating	Casein kinase I isoform delta	Homo sapiens (human)
spindle assembly	Casein kinase I isoform delta	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Casein kinase I isoform delta	Homo sapiens (human)
midbrain dopaminergic neuron differentiation	Casein kinase I isoform delta	Homo sapiens (human)
cellular response to nerve growth factor stimulus	Casein kinase I isoform delta	Homo sapiens (human)
positive regulation of non-canonical Wnt signaling pathway	Casein kinase I isoform delta	Homo sapiens (human)
peptidyl-serine phosphorylation	Casein kinase I isoform delta	Homo sapiens (human)
signal transduction	Casein kinase I isoform delta	Homo sapiens (human)
non-motile cilium assembly	Casein kinase I isoform delta	Homo sapiens (human)
endocytosis	Casein kinase I isoform delta	Homo sapiens (human)
DNA repair	Casein kinase I isoform epsilon	Homo sapiens (human)
protein phosphorylation	Casein kinase I isoform epsilon	Homo sapiens (human)
protein localization	Casein kinase I isoform epsilon	Homo sapiens (human)
negative regulation of Wnt signaling pathway	Casein kinase I isoform epsilon	Homo sapiens (human)
negative regulation of protein binding	Casein kinase I isoform epsilon	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Casein kinase I isoform epsilon	Homo sapiens (human)
regulation of protein localization	Casein kinase I isoform epsilon	Homo sapiens (human)
circadian regulation of gene expression	Casein kinase I isoform epsilon	Homo sapiens (human)
regulation of circadian rhythm	Casein kinase I isoform epsilon	Homo sapiens (human)
circadian behavior	Casein kinase I isoform epsilon	Homo sapiens (human)
canonical Wnt signaling pathway	Casein kinase I isoform epsilon	Homo sapiens (human)
positive regulation of amyloid-beta formation	Casein kinase I isoform epsilon	Homo sapiens (human)
cellular response to nerve growth factor stimulus	Casein kinase I isoform epsilon	Homo sapiens (human)
positive regulation of non-canonical Wnt signaling pathway	Casein kinase I isoform epsilon	Homo sapiens (human)
peptidyl-serine phosphorylation	Casein kinase I isoform epsilon	Homo sapiens (human)
endocytosis	Casein kinase I isoform epsilon	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Casein kinase I isoform epsilon	Homo sapiens (human)
signal transduction	Casein kinase I isoform epsilon	Homo sapiens (human)
double-strand break repair	Casein kinase II subunit alpha	Homo sapiens (human)
protein phosphorylation	Casein kinase II subunit alpha	Homo sapiens (human)
apoptotic process	Casein kinase II subunit alpha	Homo sapiens (human)
DNA damage response	Casein kinase II subunit alpha	Homo sapiens (human)
signal transduction	Casein kinase II subunit alpha	Homo sapiens (human)
positive regulation of cell population proliferation	Casein kinase II subunit alpha	Homo sapiens (human)
Wnt signaling pathway	Casein kinase II subunit alpha	Homo sapiens (human)
negative regulation of translation	Casein kinase II subunit alpha	Homo sapiens (human)
peptidyl-serine phosphorylation	Casein kinase II subunit alpha	Homo sapiens (human)
peptidyl-threonine phosphorylation	Casein kinase II subunit alpha	Homo sapiens (human)
positive regulation of Wnt signaling pathway	Casein kinase II subunit alpha	Homo sapiens (human)
positive regulation of cell growth	Casein kinase II subunit alpha	Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	Casein kinase II subunit alpha	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	Casein kinase II subunit alpha	Homo sapiens (human)
positive regulation of protein catabolic process	Casein kinase II subunit alpha	Homo sapiens (human)
rhythmic process	Casein kinase II subunit alpha	Homo sapiens (human)
protein stabilization	Casein kinase II subunit alpha	Homo sapiens (human)
chaperone-mediated protein folding	Casein kinase II subunit alpha	Homo sapiens (human)
symbiont-mediated disruption of host cell PML body	Casein kinase II subunit alpha	Homo sapiens (human)
positive regulation of aggrephagy	Casein kinase II subunit alpha	Homo sapiens (human)
regulation of chromosome separation	Casein kinase II subunit alpha	Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombination	Casein kinase II subunit alpha	Homo sapiens (human)
negative regulation of apoptotic signaling pathway	Casein kinase II subunit alpha	Homo sapiens (human)
regulation of cell cycle	Casein kinase II subunit alpha	Homo sapiens (human)
protein phosphorylation	Casein kinase I isoform gamma-2	Homo sapiens (human)
Wnt signaling pathway	Casein kinase I isoform gamma-2	Homo sapiens (human)
sphingolipid biosynthetic process	Casein kinase I isoform gamma-2	Homo sapiens (human)
signal transduction	Casein kinase I isoform gamma-2	Homo sapiens (human)
peptidyl-serine phosphorylation	Casein kinase I isoform gamma-2	Homo sapiens (human)
endocytosis	Casein kinase I isoform gamma-2	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Casein kinase I isoform gamma-2	Homo sapiens (human)
Wnt signaling pathway	Casein kinase I isoform gamma-1	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Casein kinase I isoform gamma-1	Homo sapiens (human)
signal transduction	Casein kinase I isoform gamma-1	Homo sapiens (human)
endocytosis	Casein kinase I isoform gamma-1	Homo sapiens (human)
peptidyl-serine phosphorylation	Casein kinase I isoform gamma-1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
protein domain specific binding	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
ubiquitin protein ligase binding	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
protein kinase A catalytic subunit binding	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
identical protein binding	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
protein kinase activity	Protein kinase C alpha type	Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activity	Protein kinase C alpha type	Homo sapiens (human)
calcium,diacylglycerol-dependent serine/threonine kinase activity	Protein kinase C alpha type	Homo sapiens (human)
integrin binding	Protein kinase C alpha type	Homo sapiens (human)
protein binding	Protein kinase C alpha type	Homo sapiens (human)
ATP binding	Protein kinase C alpha type	Homo sapiens (human)
zinc ion binding	Protein kinase C alpha type	Homo sapiens (human)
enzyme binding	Protein kinase C alpha type	Homo sapiens (human)
histone H3T6 kinase activity	Protein kinase C alpha type	Homo sapiens (human)
protein serine kinase activity	Protein kinase C alpha type	Homo sapiens (human)
protein serine/threonine kinase activity	Protein kinase C alpha type	Homo sapiens (human)
diacylglycerol binding	Protein kinase C alpha type	Homo sapiens (human)
protein kinase activity	Casein kinase I isoform alpha	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase I isoform alpha	Homo sapiens (human)
protein binding	Casein kinase I isoform alpha	Homo sapiens (human)
ATP binding	Casein kinase I isoform alpha	Homo sapiens (human)
protein serine kinase activity	Casein kinase I isoform alpha	Homo sapiens (human)
protein kinase activity	Casein kinase I isoform delta	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase I isoform delta	Homo sapiens (human)
protein binding	Casein kinase I isoform delta	Homo sapiens (human)
ATP binding	Casein kinase I isoform delta	Homo sapiens (human)
cadherin binding	Casein kinase I isoform delta	Homo sapiens (human)
tau-protein kinase activity	Casein kinase I isoform delta	Homo sapiens (human)
protein serine kinase activity	Casein kinase I isoform delta	Homo sapiens (human)
RNA binding	Casein kinase I isoform epsilon	Homo sapiens (human)
protein kinase activity	Casein kinase I isoform epsilon	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase I isoform epsilon	Homo sapiens (human)
protein binding	Casein kinase I isoform epsilon	Homo sapiens (human)
ATP binding	Casein kinase I isoform epsilon	Homo sapiens (human)
protein serine kinase activity	Casein kinase I isoform epsilon	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase II subunit alpha	Homo sapiens (human)
protein binding	Casein kinase II subunit alpha	Homo sapiens (human)
ATP binding	Casein kinase II subunit alpha	Homo sapiens (human)
kinase activity	Casein kinase II subunit alpha	Homo sapiens (human)
identical protein binding	Casein kinase II subunit alpha	Homo sapiens (human)
Hsp90 protein binding	Casein kinase II subunit alpha	Homo sapiens (human)
protein serine kinase activity	Casein kinase II subunit alpha	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase I isoform gamma-2	Homo sapiens (human)
protein binding	Casein kinase I isoform gamma-2	Homo sapiens (human)
ATP binding	Casein kinase I isoform gamma-2	Homo sapiens (human)
protein serine kinase activity	Casein kinase I isoform gamma-2	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase I isoform gamma-1	Homo sapiens (human)
protein binding	Casein kinase I isoform gamma-1	Homo sapiens (human)
ATP binding	Casein kinase I isoform gamma-1	Homo sapiens (human)
protein serine kinase activity	Casein kinase I isoform gamma-1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Calcium/calmodulin-dependent protein kinase II inhibitor 2	Bos taurus (cattle)
cytosol	Calcium/calmodulin-dependent protein kinase II inhibitor 2	Bos taurus (cattle)
synapse	Calcium/calmodulin-dependent protein kinase II inhibitor 2	Bos taurus (cattle)
immunological synapse	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
cytoplasm	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
multivesicular body	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
centrosome	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
axoneme	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
neuromuscular junction	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
plasma membrane raft	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
sperm head-tail coupling apparatus	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
glutamatergic synapse	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
cAMP-dependent protein kinase complex	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
nucleotide-activated protein kinase complex	cAMP-dependent protein kinase type I-alpha regulatory subunit [Cleaved into: cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed]	Bos taurus (cattle)
ciliary basal body	Protein kinase C alpha type	Homo sapiens (human)
nucleoplasm	Protein kinase C alpha type	Homo sapiens (human)
cytoplasm	Protein kinase C alpha type	Homo sapiens (human)
mitochondrion	Protein kinase C alpha type	Homo sapiens (human)
endoplasmic reticulum	Protein kinase C alpha type	Homo sapiens (human)
cytosol	Protein kinase C alpha type	Homo sapiens (human)
plasma membrane	Protein kinase C alpha type	Homo sapiens (human)
mitochondrial membrane	Protein kinase C alpha type	Homo sapiens (human)
perinuclear region of cytoplasm	Protein kinase C alpha type	Homo sapiens (human)
extracellular exosome	Protein kinase C alpha type	Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complex	Protein kinase C alpha type	Homo sapiens (human)
mRNA cleavage and polyadenylation specificity factor complex	Casein kinase I isoform alpha	Homo sapiens (human)
keratin filament	Casein kinase I isoform alpha	Homo sapiens (human)
kinetochore	Casein kinase I isoform alpha	Homo sapiens (human)
centrosome	Casein kinase I isoform alpha	Homo sapiens (human)
spindle	Casein kinase I isoform alpha	Homo sapiens (human)
cytosol	Casein kinase I isoform alpha	Homo sapiens (human)
cilium	Casein kinase I isoform alpha	Homo sapiens (human)
membrane	Casein kinase I isoform alpha	Homo sapiens (human)
nuclear speck	Casein kinase I isoform alpha	Homo sapiens (human)
beta-catenin destruction complex	Casein kinase I isoform alpha	Homo sapiens (human)
ciliary basal body	Casein kinase I isoform alpha	Homo sapiens (human)
cytoplasm	Casein kinase I isoform alpha	Homo sapiens (human)
nucleus	Casein kinase I isoform alpha	Homo sapiens (human)
nucleus	Casein kinase I isoform delta	Homo sapiens (human)
nucleoplasm	Casein kinase I isoform delta	Homo sapiens (human)
Golgi apparatus	Casein kinase I isoform delta	Homo sapiens (human)
centrosome	Casein kinase I isoform delta	Homo sapiens (human)
spindle	Casein kinase I isoform delta	Homo sapiens (human)
cytosol	Casein kinase I isoform delta	Homo sapiens (human)
spindle microtubule	Casein kinase I isoform delta	Homo sapiens (human)
plasma membrane	Casein kinase I isoform delta	Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membrane	Casein kinase I isoform delta	Homo sapiens (human)
ciliary basal body	Casein kinase I isoform delta	Homo sapiens (human)
perinuclear region of cytoplasm	Casein kinase I isoform delta	Homo sapiens (human)
nucleus	Casein kinase I isoform delta	Homo sapiens (human)
cytoplasm	Casein kinase I isoform delta	Homo sapiens (human)
spindle microtubule	Casein kinase I isoform delta	Homo sapiens (human)
nucleus	Casein kinase I isoform epsilon	Homo sapiens (human)
nucleoplasm	Casein kinase I isoform epsilon	Homo sapiens (human)
cytoplasm	Casein kinase I isoform epsilon	Homo sapiens (human)
cytosol	Casein kinase I isoform epsilon	Homo sapiens (human)
growth cone	Casein kinase I isoform epsilon	Homo sapiens (human)
neuronal cell body	Casein kinase I isoform epsilon	Homo sapiens (human)
ribonucleoprotein complex	Casein kinase I isoform epsilon	Homo sapiens (human)
cytoplasm	Casein kinase I isoform epsilon	Homo sapiens (human)
nucleus	Casein kinase I isoform epsilon	Homo sapiens (human)
PcG protein complex	Casein kinase II subunit alpha	Homo sapiens (human)
PML body	Casein kinase II subunit alpha	Homo sapiens (human)
nucleus	Casein kinase II subunit alpha	Homo sapiens (human)
nucleoplasm	Casein kinase II subunit alpha	Homo sapiens (human)
cytosol	Casein kinase II subunit alpha	Homo sapiens (human)
plasma membrane	Casein kinase II subunit alpha	Homo sapiens (human)
protein kinase CK2 complex	Casein kinase II subunit alpha	Homo sapiens (human)
Sin3-type complex	Casein kinase II subunit alpha	Homo sapiens (human)
cytosol	Casein kinase II subunit alpha	Homo sapiens (human)
nucleus	Casein kinase II subunit alpha	Homo sapiens (human)
cytosol	Casein kinase I isoform gamma-2	Homo sapiens (human)
cell cortex	Casein kinase I isoform gamma-2	Homo sapiens (human)
membrane	Casein kinase I isoform gamma-2	Homo sapiens (human)
cytoplasm	Casein kinase I isoform gamma-2	Homo sapiens (human)
plasma membrane	Casein kinase I isoform gamma-2	Homo sapiens (human)
nucleus	Casein kinase I isoform gamma-2	Homo sapiens (human)
cytosol	Casein kinase I isoform gamma-1	Homo sapiens (human)
nucleus	Casein kinase I isoform gamma-1	Homo sapiens (human)
plasma membrane	Casein kinase I isoform gamma-1	Homo sapiens (human)
cytoplasm	Casein kinase I isoform gamma-1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (79)

Assay ID	Title	Year	Journal	Article
AID1799819	Enzyme Assay from Article : \\A newly synthesized selective casein kinase I inhibitor, N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide, and affinity purification of casein kinase I from bovine testis.\\	1989	The Journal of biological chemistry, Mar-25, Volume: 264, Issue:9	A newly synthesized selective casein kinase I inhibitor, N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide, and affinity purification of casein kinase I from bovine testis.
AID388022	Inhibition of CK1	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	Identification of novel protein kinase CK1 delta (CK1delta) inhibitors through structure-based virtual screening.
AID448716	Inhibition of GST-fused human full length CK1delta expressed in Escherichia coli at 25 uM	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta.
AID435620	Percentage p38alpha activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435866	Percentage MST2 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435481	Percentage MSK1 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID436029	Percentage PIM1 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435486	Percentage NEK7 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435632	Percentage S6K1 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435956	Percentage Aurora C activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435231	Percentage GSK3-beta activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435606	Percentage JNK2 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435125	Percentage p38delta activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435186	Percentage BRSK2 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435874	Percentage PLK1 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435703	Percentage AMPK activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID436026	Percentage PAK4 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID704331	Inhibition of Staphylococcus sp. APH(3')-3a	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	ATP-binding site of bacterial enzymes as a target for antibacterial drug design.
AID435245	Percentage MKK1 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435972	Percentage MAPKAPK3 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435590	Percentage CHK2 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435115	Percentage MARK3 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435989	Percentage RSK2 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435879	Percentage PRK2 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435816	Percentage PKBalpha activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435535	Percentage PAK5 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435862	Percentage JNK3 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID436031	Percentage PIM3 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435107	Percentage HIPK3 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435587	Percentage CDK2-cyclinA activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435716	Percentage DYRK1A activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435983	Percentage p38beta activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435918	Percentage PHK activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435996	Percentage SRPK1 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435841	Percentage Aurora B activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435708	Percentage CaMK1 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435923	Percentage PKBbeta activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435424	Percentage PKA activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435855	Percentage IKK-beta activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435227	Percentage ERK1 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435364	Percentage MNK1 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435463	Percentage DYRK3 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435623	Percentage PRAK activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435491	Percentage PKCzeta activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435220	Percentage CaMKKbeta activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435502	Percentage SmMLCK activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID436030	Percentage PIM2 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435485	Percentage NEK6 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435757	Percentage Src activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435848	Percentage DYRK2 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1539765	Inhibition of CK1 (unknown origin)	2019	European journal of medicinal chemistry, Nov-01, Volume: 181	Small molecule modulators targeting protein kinase CK1 and CK2.
AID435749	Percentage RSK1 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID448718	Inhibition of rabbit skeletal muscle CK1delta by liquid scintillation counting	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta.
AID435724	Percentage HIPK2 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435117	Percentage MELK activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435607	Percentage MAPKAPK2 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435591	Percentage CK1delta activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435744	Percentage PKD1 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435721	Percentage ERK8 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435536	Percentage PAK6 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID436069	Percentage CHK1 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435672	Percentage PKCalpha activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435710	Percentage CaMKKalpha activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435595	Percentage CK2 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435226	Percentage EF2K activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435851	Percentage ERK2 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID448715	Inhibition of GST-fused human full length p38alpha expressed in Escherichia coli at 25 uM	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta.
AID435497	Percentage ROCK2 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID684955	Inhibition of CK1 using KRRRALS(p)VASLPGL as substrate after 40 mins by scintillation counter	2012	European journal of medicinal chemistry, Oct, Volume: 56	Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization.
AID435809	Percentage PDK1 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435357	Percentage JNK1 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435478	Percentage MNK2 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435754	Percentage SGK1 activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435871	Percentage p38-gamma activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID436074	Percentage CSK activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435473	Percentage Lck activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435868	Percentage NEK2a activity remaining in the presence of 25uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1811	Experimentally measured binding affinity data derived from PDB	1996	Proceedings of the National Academy of Sciences of the United States of America, Jun-25, Volume: 93, Issue:13	Structural basis for selectivity of the isoquinoline sulfonamide family of protein kinase inhibitors.
AID977610	Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB	1996	Proceedings of the National Academy of Sciences of the United States of America, Jun-25, Volume: 93, Issue:13	Structural basis for selectivity of the isoquinoline sulfonamide family of protein kinase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (2.86)	18.7374
1990's	15 (42.86)	18.2507
2000's	12 (34.29)	29.6817
2010's	7 (20.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	3 (8.57%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	32 (91.43%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
phosphoserine Phosphoserine: The phosphoric acid ester of serine.	2.39	2	non-proteinogenic alpha-amino acid; O-phosphoamino acid; serine derivative	human metabolite
phloroglucinol Phloroglucinol: A trinitrobenzene derivative with antispasmodic properties that is used primarily as a laboratory reagent.. phloroglucinol : A benzenetriol with hydroxy groups at position 1, 3 and 5.	2.44	2	benzenetriol; phenolic donor	algal metabolite
putrescine [no description available]	1.98	1	alkane-alpha,omega-diamine	antioxidant; fundamental metabolite
spermidine [no description available]	1.98	1	polyazaalkane; triamine	autophagy inducer; fundamental metabolite; geroprotector
4,5,6,7-tetrabromo-2-azabenzimidazole 4,5,6,7-tetrabromobenzotriazole: a CK2 kinase inhibitor	3.31	1
calmidazolium calmidazolium: powerful inhibitor of or red blood cell Ca++-ATPase & Ca++ transport into inside-out red blood cell vesicles; RN refers to chloride; structure in first source; an antagonist of calmodulin. calmidazolium : An imidazolium ion that is imidazolium cation substituted by a bis(4-chlorophenyl)methyl group at position 1 and a 2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl group at position 3. It acts as an antagonist of calmodulin, a calcium binding messenger protein.	1.98	1	imidazolium ion	apoptosis inducer; calmodulin antagonist
emodin Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.. emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.	3.31	1	trihydroxyanthraquinone	antineoplastic agent; laxative; plant metabolite; tyrosine kinase inhibitor
go 6976 [no description available]	2.03	1	indolocarbazole; organic heterohexacyclic compound	EC 2.7.11.13 (protein kinase C) inhibitor
n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide [no description available]	2.03	1	isoquinolines; sulfonamide
1-(5-isoquinolinesulfonyl)-2-methylpiperazine 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.. 1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.	3.77	3	isoquinolines; N-sulfonylpiperazine	EC 2.7.11.13 (protein kinase C) inhibitor
n-(2-aminoethyl)-5-isoquinolinesulfonamide [no description available]	3.79	3
ha 1004 N-(2-guanidinoethyl)-5-isoquinolinesulfonamide: structure given in first source	3.16	1	isoquinolines
fasudil fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.	2.03	1	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent
harmaline Harmaline: A beta-carboline alkaloid isolated from seeds of PEGANUM.. harmaline : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7 and has been reduced across the 3,4 bond.	2.03	1	harmala alkaloid	oneirogen
harmalol harmalol: inhibitor of rat liver microsomal UDP-glucuronyltransferase; RN given refers to parent cpd; structure. harmalol : A harmala alkaloid in which the harman skeleton is hydroxy-substituted at C-7 and has been reduced across the 3,4 bond.	2.03	1	harmala alkaloid	algal metabolite; EC 1.4.3.4 (monoamine oxidase) inhibitor
ic 261 [no description available]	2.96	4	indoles
nsc 664704 kenpaullone: inhibits CDK1/cyclin B; structure in first source. kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).	2.03	1	indolobenzazepine; lactam; organobromine compound	cardioprotective agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; geroprotector
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.03	1	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
ml 7 ML-7 : An N-sulfonyldiazepane resullting from the formal condensation of 5-iodo-1-naphthylsulfonic acid with one of the nitrogens of 1,4-diazepane. It is a selective inhibitor of myosin light chain kinase (EC 2.7.11.18).	1.98	1	N-sulfonyldiazepane; organoiodine compound	EC 2.7.11.18 (myosin-light-chain kinase) inhibitor
1-NA-PP1 [no description available]	2.03	1	pyrazolopyrimidine	tyrosine kinase inhibitor
ag 1879 3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor	2.03	1	aromatic amine; monochlorobenzenes; pyrazolopyrimidine	beta-adrenergic antagonist; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
1,2,5,8-tetrahydroxy anthraquinone 1,2,5,8-tetrahydroxy anthraquinone: structure in first source. quinalizarin : A tetrahydroxyanthraquinone having the four hydroxy groups at the 1-, 2-, 5- and 8-positions.	3.31	1	tetrahydroxyanthraquinone	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
ro 31-8220 Ro 31-8220: a protein kinase C inhibitor	2.03	1	imidothiocarbamic ester; indoles; maleimides	EC 2.7.11.13 (protein kinase C) inhibitor
sb 202190 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase	2.44	2	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
w 7 W 7: RN given refers to parent cpd; structure; calmodulin antagonist	2.39	2
zm 336372 N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide: an inhibitor of c-Raf; activates Raf-1; structure in first source	2.03	1	benzamides
dichlororibofuranosylbenzimidazole Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.	2.42	2
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	2.02	1	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.02	1	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
1,4-dihydroxyanthraquinone 1,4-dihydroxyanthraquinone: structure given in first source. quinizarin : A dihydroxyanthraquinone having the two hydroxy substituents at the 1- and 4-positions; formally derived from anthraquinone by replacement of two hydrogen atoms by hydroxy groups	2.04	1	dihydroxyanthraquinone	dye
1-amino-4-hydroxyanthraquinone [no description available]	2.04	1
pyrazolanthrone pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.	2.03	1	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
5-methoxyindole 5-methoxyindole: structure in first source	3.16	1	indoles
tetradecanoylphorbol acetate Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.	2.02	1	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
1,4-diaminoanthraquinone [no description available]	2.04	1
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.02	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
ml 9 [no description available]	3.07	1
5'-thioadenosine 5'-thioadenosine: structure given in first source	3.16	1
ruboxistaurin ruboxistaurin: inhibits protein kinase C beta; structure in first source	2.03	1
birb 796 [no description available]	2.03	1	aromatic ether; morpholines; naphthalenes; pyrazoles; ureas	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	2.03	1	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
sb 203580 [no description available]	2.44	2	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
sb 216763 [no description available]	2.03	1	indoles; maleimides
sorafenib [no description available]	2.03	1	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
wortmannin [no description available]	2.03	1	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
leptomycin b [no description available]	2.02	1
cyanoginosin lr cyanoginosin LR: cyclic heptapeptide from cyanobacterium Microcystis aeruginosa. microcystin-LR : A microcystin consisting of D-alanyl, L-leucyl, (3S)-3-methyl-D-beta-aspartyl,L-arginyl, 2S,3S,4E,6E,8S,9S)-3-amino-4,5,6,7-tetradehydro-9-methoxy-2,6,8-trimethyl-10-phenyldecanoyl, D-gamma-glutamyl, and 2,3-didehydro-N-methylalanyl residues joined into a 25-membered macrocycle. Produced by the cyanobacterium Microcystis aeruginosa, it is the most studied of the microcystins.	2.05	1	microcystin	bacterial metabolite; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; environmental contaminant; xenobiotic
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea: structure in first source	2.03	1
y 27632 Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source. Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme.	2.44	2	aromatic amide
h 1152 (S)-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1,4-diazepane : A member of the class of isoquinolines that is the sulfonamide formed by the formal condensation of the sulfo group of 4-methylisoquinoline-5-sulfonic acid with the 1-amino group of (S)-2-methyl-1,4-diazepane.	2.03	1	isoquinolines; N-sulfonyldiazepane	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
h 89 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide: structure given in first source. N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.. (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide in which the double bond adopts a trans-configuration.	3.78	3	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
purvalanol a 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine: purvalanol A is the (1R)-isomer;	2.03	1	purvalanol
Src Inhibitor-1 Src Inhibitor-1 : A member of the class of quinazolines that is quinazoline which is substituted at position 4 by a p-phenoxyanilino group and at positions 6 and 7 by methoxy groups. It is a potent, competitive dual site (both the ATP- and peptide-binding) Src kinase inhibitor. Src Inhibitor-1 is one of the 'gold standards' for Src kinase inhibition that has been shown to use PP1 or PP2 in parallel with Src-I1 to inhbit Src family kinases.	2.03	1	aromatic ether; polyether; quinazolines; secondary amino compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
sc 514 SC 514: inhibits IkappaB kinase-2; structure in first source	2.03	1	ring assembly; thiophenes
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.03	1	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
7-epi-hydroxystaurosporine [no description available]	2.03	1
sb 415286 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione: a glycogen synthase kinase-3 inhibitor; structure in first source	2.03	1	C-nitro compound; maleimides; monochlorobenzenes; phenols; secondary amino compound; substituted aniline	antioxidant; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide: a TGF-beta type I receptor kinase activity inhibitor	2.5	2	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
alsterpaullone alsterpaullone: structure in first source. alsterpaullone : An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole.	2.03	1	C-nitro compound; caprolactams; organic heterotetracyclic compound	anti-HIV-1 agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor
4,5,6,7-tetrabromobenzimidazole 4,5,6,7-tetrabromobenzimidazole: structure in first source	3.31	1
1-tert-butyl-3-naphthalen-1-ylmethyl-1h-pyrazolo(3,4-d)pyrimidin-4-ylemine [no description available]	2.03	1	pyrazolopyrimidine	tyrosine kinase inhibitor
quercetin [no description available]	3.31	1	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	3.31	1	trihydroxyflavone	antineoplastic agent; metabolite
harmine Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's.. harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7.	2.03	1	harmala alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; metabolite
harman harman: a beta-carboline; RN given refers to parent cpd; structure. harman : An indole alkaloid fundamental parent with a structure of 9H-beta-carboline carrying a methyl substituent at C-1. It has been isolated from the bark of Sickingia rubra, Symplocus racemosa, Passiflora incarnata, Peganum harmala, Banisteriopsis caapi and Tribulus terrestris, as well as from tobacco smoke. It is a specific, reversible inhibitor of monoamine oxidase A.	2.03	1	harmala alkaloid; indole alkaloid fundamental parent; indole alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
fisetin [no description available]	3.31	1	3'-hydroxyflavonoid; 7-hydroxyflavonol; tetrahydroxyflavone	anti-inflammatory agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; metabolite; plant metabolite
coumestrol Coumestrol: A daidzein derivative occurring naturally in forage crops which has some estrogenic activity.. coumestrol : A member of the class of coumestans that is coumestan with hydroxy substituents at positions 3 and 9.	3.31	1	coumestans; delta-lactone; polyphenol	anti-inflammatory agent; antioxidant; plant metabolite
rottlerin rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1);. rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis.	2.03	1	aromatic ketone; benzenetriol; chromenol; enone; methyl ketone	anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite
ellagic acid [no description available]	3.31	1	catechols; cyclic ketone; lactone; organic heterotetracyclic compound; polyphenol	antioxidant; EC 1.14.18.1 (tyrosinase) inhibitor; EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitor; EC 2.4.1.1 (glycogen phosphorylase) inhibitor; EC 2.5.1.18 (glutathione transferase) inhibitor; EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitor; EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitor; EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; food additive; fungal metabolite; geroprotector; plant metabolite; skin lightening agent
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.03	1	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
ic 261 IC 261: a caseine kinase-1 inhibitor; structure in first source	2.44	2
kn 62 KN 62: inhibitor of Ca/calmodulin-dependent protein kinase II	3.77	3	piperazines
su 6656 SU 6656: a c-Src kinase inhibitor; used to probe growth signaling; structure in first source. SU6656 : A member of the class of oxindoles that is 3-methyleneoxindole in which the hydrogeh at position 5 has been replaced by a dimethylaminosulfonyl group and in which one of the hydrogens of the methylene group has been replaced by a 4,5,6,7-tetrahydro-indol-2-yl group. It is a specific inhibitor of Src family kinase.	2.03	1
casein kinase ii Casein Kinase II: A ubiquitous casein kinase that is comprised of two distinct catalytic subunits and dimeric regulatory subunit. Casein kinase II has been shown to phosphorylate a large number of substrates, many of which are proteins involved in the regulation of gene expression.	4.02	4
orantinib orantinib: an antiangiogenic agent. orantinib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is substituted by a 2-(2-carboxyethyl)-3,5-dimethylpyrrol-3-yl group. It is an ATP-competitive inhibitor of the tyrosine kinase activity of fibroblast growth factor receptor 1.	2.03	1
vx680 [no description available]	2.03	1	N-arylpiperazine
3,8-dibromo-7-hydroxy-4-methylchromen-2-one 3,8-dibromo-7-hydroxy-4-methylchromen-2-one: structure in first source	3.31	1	hydroxycoumarin
monorden monorden: inhibits HSP90 Heat-Shock Proteins, DNA topoisomerase VI and human Topoisomerase II	3.16	1	cyclic ketone; enone; epoxide; macrolide antibiotic; monochlorobenzenes; phenols	antifungal agent; metabolite; tyrosine kinase inhibitor
d 4476 [no description available]	4.26	5	imidazoles
pd 184352 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source	2.03	1	aminobenzoic acid
staurosporine staurosporinium : Conjugate acid of staurosporine.	1.99	1	ammonium ion derivative
bms345541 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline: structure in first source	2.03	1	quinoxaline derivative
pd 0325901 mirdametinib: has antineoplastic activity; appears to be a MEK inhibitor. PD 0325901 : A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer).	2.03	1	difluorobenzene; hydroxamic acid ester; monofluorobenzenes; organoiodine compound; propane-1,2-diols; secondary amino compound	antineoplastic agent; EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
pi103 PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce	2.03	1	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
ps1145 PS1145: IkappaB kinase inhibitor; structure in first source	2.03	1	beta-carbolines
chir 99021 Chir 99021: structure in first source. CHIR 99021 : A member of the class of aminopyrimidines that is 2-aminopyrimidine substituted at positions N2, 5 and 6 by (5-cyanopyridin-2-yl)ethyl, 4-methylimidazol-2-yl and 2,4-dichlorophenyl groups respectively.	2.03	1	aminopyridine; aminopyrimidine; cyanopyridine; diamine; dichlorobenzene; imidazoles; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor
bx795 BX795: structure in first source	2.03	1	ureas
a 443654 A 443654: an Akt kinase inhibitor; structure in first source	2.03	1	indoles
sl0101 SL0101: p90 Ribosomal S6 Kinase; structure in first source	2.03	1
dorsomorphin dorsomorphin: an AMPK inhibitor. dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling.	2.03	1	aromatic ether; piperidines; pyrazolopyrimidine; pyridines	bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
cgp 57380 CGP 57380: inhibits the mitogen-activated protein kinase-interacting kinase Mnk1	2.03	1	pyrazolopyrimidine
4-(3-cyclohexyl-5-(4-fluoro-phenyl)-3h-imidazol-4-yl)pyrimidin-2-ylamine PF-670462 free base : A member of the class of imidazoles that is 1H-imidazole which is substituted at positions 1, 4, and 5 by cyclohexyl, p-fluorophenyl, and 2-aminopyrimidin-4-yl groups, respectively. It is a selective inhibitor of the delta- and epsilon-isoforms of casein kinase 1 (CK1delta and CK1epsilon).	3.62	2	aminopyrimidine; imidazoles; monofluorobenzenes	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
acid phosphatase Acid Phosphatase: An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2.	1.99	1
(e)-3-(2,3,4,5-tetrabromophenyl)acrylic acid (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid: casein kinase II inhibitor	3.31	1
cx 4945 [no description available]	3.31	1
bi d1870 [no description available]	2.46	2
(R)-DRF053 (R)-DRF053 : A member of the class of 2,6-diaminopurines that is 2,6-diamiopurine which is substituted by an isopropyl group at position 9 and in which the amino groups at positions 2 and 6 are substituted by a 1-hydroxybutan-2-yl and 3-(pyridin-2-yl)phenyl groups, respectively (the R enantiomer). A cyclin dependent kinase inhibitor, widely used as its hydrochloride hydrate.	2.07	1	2,6-diaminopurines; phenylpyridine; primary alcohol; secondary amino compound	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
ldn 193189 LDN 193189: inhibits bone morphogenetic protein signaling	2.21	1	pyrimidines
cx 5011 [no description available]	3.31	1
pf 4800567 PF-4800567 : A pyrazolopyrimidine that is 1H-pyrazolo[3,4-d]pyrimidin-4-amine which is substituted at positions 1 and 3 by tetrahydro-2H-pyran-4-yl and (m-chlorophenoxy)methyl groups, respectively. It is a selective inhibitor of the epsilon isoform of casein kinase 1 (CK1epsilon).	3.62	2	aromatic ether; monochlorobenzenes; oxanes; pyrazolopyrimidine	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
novobiocin Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.	3.16	1	carbamate ester; ether; hexoside; hydroxycoumarin; monocarboxylic acid amide; monosaccharide derivative; phenols	antibacterial agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Escherichia coli metabolite; hepatoprotective agent
clorobiocin clorobiocin: chlorine-containing antibiotic related to novobiocin	3.16	1
okadaic acid Okadaic Acid: A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. It is produced by DINOFLAGELLATES and causes diarrhetic SHELLFISH POISONING.. okadaic acid : A polycyclic ether that is produced by several species of dinoflagellates, and is known to accumulate in both marine sponges and shellfish. A polyketide, polyether derivative of a C38 fatty acid, it is one of the primary causes of diarrhetic shellfish poisoning (DSP). It is a potent inhibitor of specific protein phosphatases and is known to have a variety of negative effects on cells.	1.99	1	ketal
akt-i-1,2 compound Akt-I-1,2 compound: an aminopeptidase P inhibitor; structure in first source	2.03	1
guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.	2.68	3	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
concanavalin a Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.	2.02	1
phosphorus radioisotopes Phosphorus Radioisotopes: Unstable isotopes of phosphorus that decay or disintegrate emitting radiation. P atoms with atomic weights 28-34 except 31 are radioactive phosphorus isotopes.	1.99	1

Condition	Relationship Strength	Studies
Bacterial Disease [description not available]	2.98	1
Bacterial Infections Infections by bacteria, general or unspecified.	2.98	1
Black Fever [description not available]	2.1	1
Leishmaniasis, Visceral A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.	2.1	1
Hepatocellular Carcinoma [description not available]	1.99	1
Cancer of Liver [description not available]	1.99	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	1.99	1
Liver Neoplasms Tumors or cancer of the LIVER.	1.99	1
Acute Confusional Senile Dementia [description not available]	1.99	1
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	1.99	1
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	2.89	1

cki 7

Description

Cross-References

Synonyms (31)

Research Excerpts

Bioavailability

Roles (1)

Drug Classes (4)

Protein Targets (11)

Inhibition Measurements

Biological Processes (96)

Molecular Functions (21)

Ceullar Components (42)

Bioassays (79)

Research

Studies (35)

Market Indicators

Research Demand Index: 19.78

Study Types

cki 7

Description

Cross-References

Synonyms (31)

Research Excerpts

Bioavailability

Roles (1)

Drug Classes (4)

Protein Targets (11)

Inhibition Measurements

Biological Processes (96)

Molecular Functions (21)

Ceullar Components (42)

Bioassays (79)

Research

Studies (35)

Market Indicators

Research Demand Index: 19.78

Study Types

Related Drugs (107)

Related Conditions (11)